@article{ATM7761,
author = {Nicholas Zaorsky and Mark Hallman and Marc Smaldone},
title = {Radiation therapy to the primary tumor in locally advanced prostate cancer is not “closing the barn door after the horse has bolted”},
journal = {Annals of Translational Medicine},
volume = {3},
number = {18},
year = {2015},
keywords = {},
abstract = {The National Cancer Institute of Canada (NCIC) Clinical Trials Group PR.3/Medical Research Council PR07/ Intergroup T94-0110 (1) was a randomized controlled trial (RCT) of radiation therapy (RT) and androgen deprivation therapy (ADT) vs. ADT alone, for men with locally advanced prostate cancer. The authors defined locally advanced as: (I) T3-4, N0/X, M0; or (II) T1-2 with prostate specific antigen (PSA) > 40 ng/mL; or (III) PSA 20-40 ng/mL and Gleason 8-10. Men were randomized to lifelong ADT vs. ADT + RT, 65-69 Gy in 1.8 Gy fractions, using 3D conformal RT, to the prostate and pelvis or prostate alone. Of the 1,205 patients treated between 1995 and 2005, 602 received ADT alone and 603 received ADT + RT. Overall survival (OS) was significantly improved in the patients allocated to ADT + RT [hazard ratio (HR) =0.70; 95% CI, 0.57-0.85; P},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/7761}
}